Neuroendocrine cancer is exceedingly difficult to manage and unlikely to be cured, but researchers intend to slow progression of these tumours and aid survival by personalising patient dose of peptide-receptor radionuclide therapy (PRRT), according to research presented at the 2017 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI).

The abstract is published in The Journal of Nuclear Imaging.

PRRT has become a treatment of choice for relatively rare and easy-to-overlook neuroendocrine tumours (NETs).

The targeted treatment is designed to home in on and attach to peptide-receptor positive tumours, while sparing tissues that might otherwise be damaged by systemic treatments. However, researchers are still perfecting the practice.

"So far, the majority of PRRT treatments have been administered one-size-fits-all, meaning every patient receives about the same amount of radioactivity," said Jean-Mathieu Beauregard, MD, assistant professor in the Department of Radiology and Nuclear Medicine at Université Laval in Quebec City, Quebec, Canada. "This results in highly variable absorbed radiation doses to organs and tumours. Many patients may not draw the maximum benefits from PRRT because they end up receiving a lesser dose than their body can realistically tolerate."

For this study, researchers used a PRRT called lutetium-177 (177Lu)-octreotate, which mimics the somatostatin growth-inhibiting hormone.

Ordinarily, patients receive a fixed amount of radioactivity, such as 200 millicuries, in several sequential cycles.

This marks the first time that 177Lu-octreotate PRRT has been matched to the patient's individual tolerance based on finely tuned SPECT dosimetry that evaluates how much radiation is building up in key organs like the kidneys.

A total of 27 neuroendocrine cancer patients underwent 55 personalised 177Lu-octreotate cycles from April to December 2016, followed by quantitative SPECT dosimetry.

Radiation dose was quantified for the kidneys to optimise the administered amount of radioactivity, while remaining safe and well tolerated by patients.

Side effects were recorded and blood counts, as well as renal and hepatic biochemistry, were performed at two, four and six weeks after each cycle of treatment.

Results showed an increase in the radiation dose to tumours for a majority of participants--increases as high as three times the dose delivered with conventional PRRT.

Furthermore, serious side effects and toxicity remained infrequent with the personalised approach.

Additional research is planned for the coming months to determine how personalised PRRT results in improved therapeutic benefits, such as reduced tumour progression and longer survival.

Source: The Society of Nuclear Medicine